CAMBRIDGE, MA — August 12, 2012 — The Intellectual Property & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, today announced that Genospace joined its Life Sciences Partner Ecosystem. The companies will work together to develop an integrated product offering for the analysis and interpretation of human genomic variation.
The Genospace platform seeks to establish secure, cloud-based online communities and customized research portals that connect physicians, individuals, and researchers who are interested in using clinical and genomic information; as well as to provide analysis and interpretation tools that support personalized medicine. An essential part of this process will be the detection and annotation of gene variants. Thomson Reuters is in the unique position to collect, annotate and publish a gene variant database and will work with Genospace to make this data available to its customers.
Through the Thomson Reuters Life Sciences Partner Ecosystem, the Genospace platform will provide access to an unprecedented amount of curated, medically relevant data – from pathway and disease biology to regulatory and financial information. The combination of Genospace’s expertise in integrating clinical and complex -omics data, coupled with the proven history of manual curation of complex data by Thomson Reuters, the partnership will help enable the realization of personalized medicine. Thomson Reuters and Genospace will produce a curated database of genomic variation, with an emphasis on medical and scientific utility.
“The barrier to establishing personalized medicine is no longer generating data, but analyzing and interpreting it,” said John Quackenbush, Genospace’s CEO. “By coupling our technology to synthesize genomic and clinical data with the unparalleled information resources that Thomson Reuters has created, we are positioned to lead the implementation of personalized medicine.”
“We are delighted to welcome Genospace to our Partner Ecosystem,” said Joseph Donahue, senior vice president at Thomson Reuters. “Together, we will be able to provide hospitals, health systems, disease foundations and pharmaceutical research organizations with large scale clinical genomic data sets and tools to help in annotating and interpreting genomic variation and support better informed medical treatment decisions”.
Genospace, LLC, is a Cambridge, Massachusetts-based company that is pioneering a bold and innovative software platform for advancing 21st-century genomic medicine. Founded in 2011 on the principle that individuals should own and control access to their own genomic data, Genospace has built a robust software system for securely storing vast amounts of genomic data and making it available to individuals and groups who need to connect with each other and share data. Please visit www.genospace.com for more information.
About Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
Chief Executive Officer
Intellectual Property Solutions